Healthcare company Organon (NYSE:OGN) said on Monday that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD).
The transaction is subject to Hart-Scott-Rodino review and US Food and Drug Administration (FDA) approval of alternate supply chain entities.
MIUDELLA, the first hormone-free copper IUD approved in the United States in 40 years, received FDA approval in February 2025 for up to three years of pregnancy prevention but is not yet commercially available. The device features a flexible frame and a preloaded inserter with a 3.7mm tapered insertion tube.
Under the deal, Organon will pay USD27.5m at closing, with potential sales-based milestone payments of up to USD505m and tiered double-digit royalties on net sales.
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Zylox-Tonbridge agrees staged acquisition of Germany's Optimed
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
Boston Scientific to acquire Valencia Technologies to expand overactive bladder portfolio
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Antin to acquire clinical trial equipment provider Emsere
Hyphens Pharma licenses Cerapro skin cream to Louis Widmer for six European markets
Profusa signs French distributor to expand Lumee Oxygen rollout in Europe
Sensiva Health names new chief operating officer
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round